Technology

PrimeLink HydramiX ADC Technology Platform

PrimeLink HydramiX ADC is a versatile and highly hydrophilic platform designed to seamlessly integrate with existing tools for each ADC module. It is compatible with a wide range of current technologies, and is capable of conjugating various payloads with diverse mechanisms of action (MOAs), regardless of their hydrophobicity. The platform also enables precise control over the drug-to-antibody ratio (DAR), ensuring optimal efficacy. HydramiX ADC exhibits excellent stability in circulation, with favorable pharmacokinetic profiles and outstanding tolerability.

HydramiX ADC Highlights

At PrimeLink, we take a targeted approach to ADC design, tailoring each ADC to its specific tumor target. Our platform generates an ADC pool with diverse molecular structures, including different payloads and DARs, all aligned with advanced ADC technologies and target biology.

• Antibodies: We employ a range of antibody formats, including monoclonal, bispecific, nanobody, and scFv, to match the target's biological profile.
• Linker-Payload Technology: Our proprietary linker technology breaks the constraints of fixed linker-payload combinations, enabling compatibility with any clinically validated payload and significantly expanding toxin MOA diversity. 
• Site-specific conjugation: Our proprietary linker technology enables precise site-specific conjugation, allowing us to produce homogeneous ADCs with greater consistency and control.
• Flexible DARs: With our platform, we could achieve DARs up to 24, while ensuring strong CMC developability.
• Controlled Payload Release: Our technology enables precise delivery to the tumor and release of the payloads for optimized therapeutic impact.
• Next generation ADC expansion: Leveraging our extensive expertise in linker design and development, we have expanded our ADC portfolio to include innovative formats such as bispecific ADCs, immune-stimulating antibody conjugates (ISACs), protein-degrader antibody conjugates (DACs), dual-drug ADCs and antibody-oligonucleotide conjugates (AOCs).

PrimeLink Cascade Screening Platform 

The diversified ADC pool is designed to enhance our ability to address the challenge of tumor heterogeneity. Through in-house cascade screening platform, we identify optimized ADC candidates for further development.